7 results
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
drug use • Silicosis ... Diagnosis: Latent ... Active TB: • ... Treatment: Active ... #TB #Diagnosis
Tuberculosis Overview

10 million new M. tuberculosis infections/year
Facultative intracellular rod-shaped bacteria
Multidrug-resistant tuberculosis (MDR-TB) accounts for 4.6% of
drug use • Silicosis ... Diagnosis: Latent ... Active TB: • ... Treatment: Active ... #TB #Diagnosis
IDSA - Clinical Strategy to Build an Individualized Treatment Regimen for Multi-Drug Resistant Tuberculosis (MDR-TB)
 •
IDSA - Clinical ... Individualized Treatment ... are contacts of infectious ... antimicrobials #regimens #pharmacology ... drugs #steps
IDSA Recommendations for Treating Mycobacterium Tuberculosis Infection and Disease in HIV-AIDS
Treating LTBI (to prevent TB disease)
Indications:
IDSA Recommendations ... Mycobacterium Tuberculosis ... and molecular diagnostic ... #TB #IDSA #Prevention ... #HIVAIDS #pharmacology
Causes of Antibiotic Failure - Differential Diagnosis Framework
Diagnosis:
 • Non-Infectious: Malignant, Autoimmune, Drug-related (NMS, serotonin syndrome,
Immunocompromise Treatment ... ocular), Tissue activity ... • Secondary to Treatment ... (C diff) • Hospital-Acquired ... thrombophlebitis), HAP, Blood stream
Tuberculin Skin Test Interpretation - Threshold for treatment
Induration cutoff >5mm:
 • Recent exposure to an individual
Threshold for treatment ... individual with active ... drug users Induration ... individuals #Tuberculosis ... SkinTest #TST #diagnosis
IDSA Recommendations for Preventing and Treating Disseminated Mycobacterium Avium Complex in HIV-AIDS
Preventing 1st Episode of Disseminated
IDSA Recommendations ... Note: Active TB ... #Prevention #Treatment ... opportunistic #infections ... #HIVAIDS #pharmacology